BFIM
NBIX icon

Beese Fulmer Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Beese Fulmer Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$290K Sell
1,719
-915
-35% -$136K 0.02% 308
2026
Q1 		$347K Buy
2,634
+730
+38% +$96.9K 0.02% 278
2025
Q4 		$270K Buy
+1,904
New +$276K 0.02% 315

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
AS
Aware Super Sydney, Australia $7.06B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

Beese Fulmer Investment Management's NBIX Position: Q2 2026 in Review

Beese Fulmer Investment Management reduced its Neurocrine Biosciences (NBIX) stake by 35% in Q2 2026, selling an estimated $136K and leaving 1,719 shares worth $290K. The position accounts for 0.02% of the portfolio, ranked #308.

Beese Fulmer Investment Management first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. The position peaked at $347K in Q1 2026. 260 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Beese Fulmer Investment Management held 1,719 shares of Neurocrine Biosciences worth $290K as of Q2 2026.
  • Beese Fulmer Investment Management sold 915 Neurocrine Biosciences shares in Q2 2026, an estimated $136K.
  • Neurocrine Biosciences made up 0.02% of Beese Fulmer Investment Management's portfolio in Q2 2026, its #308 holding.
  • Beese Fulmer Investment Management first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Beese Fulmer Investment Management's Neurocrine Biosciences position peaked at $347K in Q1 2026.
  • 260 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Beese Fulmer Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.